0.6768
price up icon4.95%   0.0319
after-market After Hours: .67 -0.0068 -1.00%
loading
Bioxcel Therapeutics Inc stock is traded at $0.6768, with a volume of 221.54K. It is up +4.95% in the last 24 hours and up +15.73% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$0.6449
Open:
$0.63
24h Volume:
221.54K
Relative Volume:
0.46
Market Cap:
$27.16M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.0952
EPS:
-7.11
Net Cash Flow:
$-155.03M
1W Performance:
-4.78%
1M Performance:
+15.73%
6M Performance:
-73.67%
1Y Performance:
-85.41%
1-Day Range:
Value
$0.63
$0.6801
1-Week Range:
Value
$0.6201
$0.83
52-Week Range:
Value
$0.505
$5.6199

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name
Name
Bioxcel Therapeutics Inc
Name
Phone
203-643-8060
Name
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Name
Employee
74
Name
Twitter
@bioxcel_tx
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
BTAI's Discussions on Twitter

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-15-23 Downgrade Mizuho Buy → Neutral
Jul-17-23 Downgrade Guggenheim Buy → Neutral
Mar-10-23 Downgrade Jefferies Buy → Hold
Dec-01-22 Upgrade Goldman Sell → Neutral
Jul-07-22 Initiated Mizuho Buy
Apr-06-22 Reiterated BofA Securities Buy
Nov-15-21 Downgrade Goldman Neutral → Sell
Apr-09-21 Initiated Berenberg Buy
Feb-01-21 Initiated UBS Buy
Oct-30-20 Initiated Goldman Buy
Sep-02-20 Initiated Jefferies Buy
Aug-17-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Reiterated H.C. Wainwright Buy
Jun-04-20 Initiated Guggenheim Buy
Apr-01-20 Initiated BofA/Merrill Buy
Feb-26-20 Reiterated H.C. Wainwright Buy
Jan-08-20 Reiterated H.C. Wainwright Buy
Nov-12-19 Initiated SunTrust Buy
View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

pulisher
10:00 AM

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - Yahoo Finance

10:00 AM
pulisher
Oct 30, 2024

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com

Oct 30, 2024
pulisher
Oct 29, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times

Oct 29, 2024
pulisher
Oct 23, 2024

BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World

Oct 23, 2024
pulisher
Oct 19, 2024

BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN

Oct 19, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan

Oct 15, 2024
pulisher
Oct 09, 2024

BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 09, 2024

BioXcel Therapeutics reports executive transition - Investing.com India

Oct 09, 2024
pulisher
Oct 09, 2024

Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily

Oct 09, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada

Oct 03, 2024
pulisher
Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BTAI Shares Experience Decline in Value - Knox Daily

Oct 03, 2024
pulisher
Oct 01, 2024

BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Oct 01, 2024
pulisher
Sep 30, 2024

The Potential Rise in the Price of BioXcel Therapeutics Inc (BTAI) following insiders activity - Knox Daily

Sep 30, 2024
pulisher
Sep 30, 2024

BioXcel Therapeutics Inc: Weathering Stock Market Storms with 24.56M Market Cap - The InvestChronicle

Sep 30, 2024
pulisher
Sep 27, 2024

Taking on analysts’ expectations and winning: BioXcel Therapeutics Inc (BTAI) - SETE News

Sep 27, 2024
pulisher
Sep 26, 2024

BioXcel Therapeutics stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia

Sep 26, 2024
pulisher
Sep 25, 2024

BioXcel Therapeutics stock hits 52-week low at $0.53 - Investing.com

Sep 25, 2024
pulisher
Sep 25, 2024

BTAI underperforms with a -2.28 decrease in share price - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT) - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Is it a good time to sell Xcel Energy, Inc. [XEL] shares after an insider sold 2,041 shares? - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Blair William & Co. IL Has $2.01 Million Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

New Haven-based BioXcel faces delisting from Nasdaq stock exchange - Hartford Business Journal

Sep 23, 2024
pulisher
Sep 23, 2024

Gaining Ground: BioXcel Therapeutics Inc (BTAI) Closes Lower at 0.58, Down -12.13 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Charting the Course: BioXcel Therapeutics Inc’s BTAI Stock Prospects - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Xcel Energy Inc. (NASDAQ:XEL) Shares Acquired by Sei Investments Co. - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Gabelli Funds LLC Sells 12,283 Shares of Xcel Energy Inc. (NASDAQ:XEL) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

BlackSky target adjusted to $15 from $2.50 at H.C. Wainwright - TipRanks

Sep 23, 2024
pulisher
Sep 22, 2024

Summit Trail Advisors LLC Boosts Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

BlueLinx Holdings Inc. (NYSE:BXC) Shares Purchased by Massachusetts Financial Services Co. MA - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

BioXcel Therapeutics faces Nasdaq delisting risk over share price - Investing.com India

Sep 21, 2024
pulisher
Sep 20, 2024

BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com Canada

Sep 20, 2024
pulisher
Sep 20, 2024

Meiji Yasuda Asset Management Co Ltd. Has $1.13 Million Holdings in Xcel Energy Inc. (NASDAQ:XEL) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - CT Insider

Sep 20, 2024

Bioxcel Therapeutics Inc Stock (BTAI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):